

Draft Guidance on Goserelin Acetate

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Goserelin Acetate

Form/Route: Implant/Subcutaneous

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, parallel *in-vivo*
Strength: 10.8 mg
Subjects: Males patients with prostate cancer.
Additional Comments: For standardization during pharmacokinetic sampling, subjects should be fasted overnight and for up to 2 hours after insertion of the implant.

2. Type of study: Fasting
Design: Single-dose, parallel *in-vivo*
Strength: 3.6 mg
Subjects: Males patients with prostate cancer and/or female patients with breast cancer.
Additional comments: Please see comment above.

Analytes to measure: Goserelin in plasma

Bioequivalence based on (90% CI): Goserelin

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.